Following POLITICO Pro’s publication of the Commission’s Pharmaceutical Legislation Impact Assessment the future of Europe’s life sciences sector remains in sharp focus.

From the outset of this Commission, President von der Leyen’s aims — to ensure Europe has the supply of affordable medicines to meet its needs, and to support the European pharmaceutical industry to ensure that it remains an innovator and world leader — gave some hope to an industry in Europe that’s seeing investment leave its shores for Asia and the U.S.